fpioreport_red fpioreport_red

CANCERPLEX® FP – Full Panel with Immuno-Oncology (IO)

A full panel for the full picture.

Every patient’s tumor has a unique molecular profile. CANCERPLEX FP uses next-generation sequencing to analyze 400+ known genes that are relevant to oncology patient care. Unlike “hot-spot” analysis that can miss up to 20% of clinically relevant alterations,1 CANCERPLEX detects actionable alterations within the panel of genes using KEW’s exclusive GENEKEEPERSM.

Answers today. A roadmap for the future.

When you order CANCERPLEX FP, KEW doesn’t stop at delivering accurate and actionable results in one simple report. Our monitoring service will continue to keep you up to date with:

  • new developments in molecular oncology
  • newly-approved targeted FDA therapies
  • changes in indications for existing targeted therapies

Even after you’ve received your CANCERPLEX FP+IO results, we will inform you of any of these new changes that could help treat your patient’s specific genomic alteration. NO patient missed. NO treatment overlooked. NO additional biopsies required. NO wasted time.

See the full list of genes covered

Immuno-Oncology

CANCERPLEX FP includes Immuno-Oncology (IO), which will identify whether your patient is likely to respond to immune checkpoint inhibitors.

Immunotherapy is an emerging pillar of cancer treatment, using a patient’s own immune system to fight their cancer. Currently only 20 – 30% of patients have durable response. CANCERPLEX FP+IO determines a patient’s likelihood of response by identifying the mutation burden. The higher the burden, the more likely he or she is to respond favorably.2-4

Larger is better.

A panel of at least 400 genes is required to accurately determine if the patient’s tumor has a high mutation burden and is thus more likely to respond to IO therapy. This makes our panel of 400+ genes a superior test for targeting the right patients.

Receiver Operating Characteristic Sensitivity (ROCS)

rcos

CANCERPLEX FP+IO Checkpoint Inhibitors:

CTLA-4 is a protein receptor functioning as an immune checkpoint, which downregulates the immune system. CTLA-4 is found on the surface of T-cells and acts as an “off” switch when bound to CD80 or CD86 on the surface of antigen-presenting cells.

  • YERVOY® (ipilimumab): human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody

PD-1 functions as an immune checkpoint and plays an important role in downregulating the immune system by preventing the activation of T-cells, which, in turn, reduces autoimmunity and promotes self-tolerance. The inhibitory effect of PD-1 is accomplished through a dual mechanism of promoting apoptosis (programmed cell death) in antigen-specific T-cells in lymph nodes while simultaneously reducing apoptosis in regulatory T-cells (suppressor T cells).

  • KEYTRUDA® (pembrolizumab): programmed death receptor-1 (PD-1) blocking antibody
  • OPDIVO® (nivolumab): programmed death receptor-1 (PD-1) blocking antibody

PD-L1, also known as CD274, is a protein on tumor cells and the binding partner of PD-1. PD-L1 is upregulated in several tumor types as a result of gene amplification or translocation events and contributes to the malignancy of these cancers by inhibiting T cell activation.

  • TECENTRIQ™ (atezolizumab): programmed cell death-ligand 1 (PD-L1) blocking antibody

1Extended RAS Mutations and Anti-EGFR Monoclonal Antibody Survival Benefit in Metastatic Colorectal Cancer: A Meta-Analysis of Randomized, Controlled Trials. Sorich MJ, Wiese MD, Rowland A, Kichenadasse G, McKinnon RA, Karapetis CS. Ann Oncol. 2015 Jan; 26(1):13-21.

2PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. D.T. Le, J.N. Uram, H. Wang, B.R. Bartlett, H. Kemberling, A.D. Eyring, A.D. Skora, B.S. Luber, N.S. Azad, D. Laheru, B. Biedrzycki, R.C. Donehower, A. Zaheer, G.A. Fisher, T.S. Crocenzi, J.J. Lee, S.M. Duffy, R.M. Goldberg,
 de la Chapelle, M. Koshiji, F. Bhaijee, T. Huebner, R.H. Hruban, L.D. Wood, N. Cuka, D.M. Pardoll, N. Papadopoulos, K.W. Kinzler, S. Zhou, T.C. Cornish, J.M. Taube, R.A. Anders, J.R. Eshleman, B. Vogelstein, L.A. Diaz, Jr. N Engl J Med 2015; 372: 2509-20.

3Mutational Landscape Determines Sensitivity to PD-1 Blockade in Non–Small Cell Lung Cancer. Naiyer A. Rizvi, Matthew D. Hellmann, Alexandra Snyder, Pia Kvistborg, Vladimir Makarov, Jonathan J. Havel, William Lee, Jianda Yuan, Phillip Wong, Teresa S. Ho, Martin L. Miller, Natasha Rekhtman, Andre L. Moreira, Fawzia Ibrahim, Cameron Bruggeman, Billel Gasmi, Roberta Zappasodi, Yuka Maeda, Chris Sander, Edward B. Garon, Taha Merghoub, Jedd D. Wolchok, Ton N. Schumacher, Timothy A. Chan. Science. 2015 April; 03 (VOL 348 ISSUE 6230): 124-128.

4Genomic Correlates of Response to CTLA-4 Blockade in Metastatic Melanoma. Eliezer M. Van Allen, Diana Miao, Bastian Schilling, Sachet A. Shukla, Christian Blank, Lisa Zimmer, Antje Sucker, Uwe Hillen, Marnix H. Geukes Foppen, Simone M. Goldinger, Jochen Utikal, Jessica C. Hassel, Benjamin Weide, Katharina C. Kaehler, Carmen Loquai, 
Peter Mohr, Ralf Gutzmer, Reinhard Dummer, Stacey Gabriel, Catherine J. Wu, Dirk Schadendorf, Levi A. Garraway. Science. 2015 Oct; 09 (VOL 350 ISSUE 6257): 207-211.

OPDIVO®, YERVOY® and the related logo are trademarks of Bristol-Myers Squibb Company.

KEYTRUDA is a trademark of Merck Sharp & Dohme Corporation.

TECENTRIQ is a trademark of Genentech, Inc.

Precision Medicine starts here. Order CANCERPLEX